MARKET

LPCN

LPCN

Lipocine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.340
+0.010
+0.75%
After Hours: 1.330 -0.01 -0.75% 16:28 10/27 EDT
OPEN
1.320
PREV CLOSE
1.330
HIGH
1.350
LOW
1.310
VOLUME
367.65K
TURNOVER
--
52 WEEK HIGH
2.960
52 WEEK LOW
0.3010
MARKET CAP
88.02M
P/E (TTM)
-2.6913
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present results from studies suggesting that low testosterone levels may play an important role on the clinical outcomes of COVID-19 in men as well as the safety and efficacy of TLANDO™, an oral testosterone replacement therapy without a dose titration requirement, at the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America ("SMSNA"). Lipocine will outline the possible mechanisms and clinical evidence that suggests men with low testosterone have poor COVID-19 outcomes, and the rationale of using an oral testosterone therapy for men with COVID-19. Results from the previously completed dose validation ("DV") study of a fixed dose TLANDO in hypogonadal males will also be presented at the meeting. The presentations will take place virtually on November 9, 2020 from 7:00 p.m. – 9:00 p.m. EST during Session 2 (Androgens and Ejaculation/Orgasm Disorders).
PR Newswire · 10/14 12:00
Lipocine to Present at the H.C. Wainwright 4th Annual NASH Investor Conference
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, will provide an update on LPCN 1144, an oral product of bioidentical testosterone being evaluated for the treatment of non-cirrhotic, NASH at the H.C. Wainwright 4th Annual NASH Investor
PR Newswire · 09/29 13:00
Lipocine announces completion of enrollment in the LPCN 1144 lift study
Lipocine (LPCN) -1.2% announced that the last patient has been enrolled in its LiFT Phase 2 clinical study.LPCN 1144, an oral prodrug of endogenous testosterone has shown meaningful reductions of liver fat
Seekingalpha · 09/21 12:36
Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the last patient has been enrolled in its LiFT ("Liver Fat intervention with oral Testosterone") Phase 2 clinical study, a paired-biopsy study investigating
PR Newswire · 09/21 12:00
Lipocine to Participate in HC Wainwright Annual Global Investment Conference
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it will provide a corporate update at the 22nd HC Wainwright Annual Global Investment Conference. The conference will take place virtually September 14 – 16, 2020
PR Newswire · 09/08 12:00
Aimmune Therapeutics rallies on Nestle acquiring, Akcea cheers Ionis acquiring 24% remaining stake, ADiTx Therapeutics and Lipocine among major losers
Gainers: Aimmune Therapeutics (AIMT) +172%, Akcea Therapeutics (AKCA) +60%, Pro-Dex (PDEX) +16%, Kindred Biosciences (KIN) +14%, Neuronetics (STIM) +11%.Losers: ADiTx Therapeutics (ADTX) -11%, Lipocine (LPCN) -11%, Orchard Therapeutics (ORTX) -11%, CNS Pharmaceuticals (CNSP) -9%, Anchiano Therapeutics (ANCN) -8%.
Seekingalpha · 08/31 14:58
BIGC, NIO among premarket losers
Shiloh Industries (SHLO) -50% after entering into stock and asset purchase agreement with Grouper Holdings.Lipocine (LPCN) -18% on extended timeline for FDA review of Tlando application.PEDEVCO (PED) -13%.BigCommerce Holdings (BIGC) -11% on sell-side caution.NIO Limited (NIO) -8% after pricing
Seekingalpha · 08/31 12:18
Fortress Reports Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
Fortress Biotech reports positive data from CUTX-101.Lipocine suffers setback on Tlando front.Enanta presents positive data for NASH and HBV.
Seekingalpha · 08/31 04:29
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LPCN. Analyze the recent business situations of Lipocine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LPCN stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 4.64M
% Owned: 7.06%
Shares Outstanding: 65.69M
TypeInstitutionsShares
Increased
8
284.61K
New
16
452.14K
Decreased
3
86.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.75%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mahesh Patel
Chief Financial Officer/Executive Vice President
Morgan Brown
Lead Director
Stephen Hill
Director
Jeffrey Fink
Director
Richard Ono
Non-Executive Director
John Higuchi
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LPCN
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products. The Company's primary development programs are based on oral delivery solutions for bioavailable drugs. The Company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitates lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminates gastrointestinal interactions that limit bioavailability. Its lead product candidate, TLANDO, is an oral testosterone replacement therapy. Its additional pipeline includes, an oral androgen therapy for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, LPCN 1144; a once daily oral testosterone replacement therapy, TLANDO XR (LPCN 1111); an androgen therapy for the treatment of NASH cirrhosis, LPCN 1148, and an oral therapy for the prevention of preterm birth, LPCN 1107.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Lipocine Inc stock information, including NASDAQ:LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.